Dr. Owen Wallace is Site Scientific Leader, Lilly Research Center, UK. He received his B.Sc. (Hons) degree in Chemistry from University College, Cork, Ireland in 1991. He then moved to Yale University in the United States where he obtained his Ph.D. in Synthetic Organic Chemistry in 1995 with Prof. Frederick E. Ziegler.
Dr. Wallace then joined the Bristol-Myers Squibb Pharmaceutical Research Institute in Wallingford, CT as a Research Investigator. He initially contributed to projects directed towards Alzheimer's disease before transitioning to the infectious disease area where he worked on new approaches to treating HIV infection. During this period, Dr. Wallace contributed to the discovery of several drug candidates.
In 2000, he moved to Eli Lilly & Company and began to work in the area of endocrinology, initially on projects targeting women's health disorders (uterine fibroids and hot flushes). He then transitioned to research in the metabolic disorders field where he led a project for type 2 diabetes. He has been named as a co-inventor of seven clinical candidates and has been a scientific team leader on projects that have delivered four candidates.
In 2003, Dr. Wallace was promoted to Head, Lead Optimisation, Discovery Chemistry Research and Technologies, and was promoted to Senior Director, Neuroscience and Obesity Chemistry in 2005 with responsibilities for medicinal chemistry on projects for Alzheimer's disease, depression, schizophrenia, pain and obesity.
In 2010, he transferred to the UK to become Site Scientific Leader of the Surrey-based Lilly Research Centre where he is accountable for the discovery of drug candidates targeting Neuroscience indications. He has direct responsibility for the Chemistry organisation, in addition to the bioanalytical group and new target enablement biology group. He has championed an in-sourcing initiative that has increased the size of the group by ~50%, and is a member of the steering committees for multiple collaborations responsible for the discovery and clinical development of compounds for CNS disorders and diabetes
Dr. Wallace is a co-author/inventor on numerous peer reviewed publications and patents.